利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.028 秒)

    Drug-containing sustained release microparticle, process for producing the same and preparation containing the microparticle
    21.
    发明申请
    Drug-containing sustained release microparticle, process for producing the same and preparation containing the microparticle 审中-公开
    含药缓释微粒，其制造方法和含有微粒的制剂

    公开(公告)号：US20060153930A1

    公开(公告)日：2006-07-13

    申请号：US10559512

    申请日：2004-06-11

    申请人： Yutaka Mizushima ,  Yasuaki Ogawa ,  Junzo Tanaka ,  Toshiyuki Ikoma

    发明人： Yutaka Mizushima ,  Yasuaki Ogawa ,  Junzo Tanaka ,  Toshiyuki Ikoma

    IPC分类号： A61K33/42

    CPC分类号： A61K31/00 ,  A61K9/1611 ,  A61K33/30 ,  A61K33/42 ,  A61K45/06 ,  A61K2300/00

    摘要： Sustained release microparticles suitable for various types of drugs, or drug-containing sustained release microparticles capable of sustained release of drugs over a period of three days or more and capable of inhibiting initial burst release; a process for producing the same; and preparations containing the microparticles are disclosed. The drug-containing sustained release microparticles comprise a drug other than human growth hormone and a porous apatite derivative, and optionally include a water-soluble bivalent metal compound. The drug-containing sustained release microparticles can be produced by dispersing under agitation microparticles of a porous apatite derivative in an aqueous solution containing a drug so that the aqueous solution infiltrates into the porous apatite derivative; optionally adding an aqueous solution containing a water-soluble bivalent metal compound that may infiltrate into the porous apatite derivative; further adding additives such as a stabilizer to the mixture; and effecting lyophilization or vacuum drying.

    摘要翻译： 适用于各种类型药物的持续释放微粒，或能够在三天或更长时间内持续释放药物并且能够抑制初始爆发释放的药物持续释放微粒; 其制造方法; 并且公开了含有微粒的制剂。 含药物的缓释微粒包含除人生长激素以外的药物和多孔磷灰石衍生物，任选地包含水溶性二价金属化合物。 含药缓释微粒可以通过将多孔磷灰石衍生物的微粒分散在含有药物的水溶液中分散而制成，使得水溶液渗透到多孔磷灰石衍生物中; 任选地加入含有可渗透到多孔磷灰石衍生物中的水溶性二价金属化合物的水溶液; 进一步向混合物中加入稳定剂等添加剂; 并进行冻干或真空干燥。

    Osteogenesis promoter and osteoporosis remedy
    22.
    发明授权
    Osteogenesis promoter and osteoporosis remedy 失效
    骨质疏松症和骨质疏松症

    公开(公告)号：US5565444A

    公开(公告)日：1996-10-15

    申请号：US537743

    申请日：1995-11-13

    申请人： Yutaka Mizushima ,  Yasuo Suzuki

    发明人： Yutaka Mizushima ,  Yasuo Suzuki

    IPC分类号： A61K31/565 ,  A61K31/56

    CPC分类号： A61K31/5685 ,  A61K31/565

    摘要： An osteogenesis promoter and/or osteoporosis remedy comprising, as an active ingredient, an androgen derivative represented by the following formula (1): ##STR1## wherein each broken line indicates that the relevant carbon-to-carbon bond is a single bond or a double bond or a salt thereof. The compound (1) activates osteoblasts, promotes osteogenesis and increases the bone mass, so that it is used for the treatment of a morbid condition of lowered osteogenesis due to aging, immobilization, administration of glucocorticoids and so forth. Further, it can increase the bone mass by its osteogenesis promoting effect so that it is useful for the treatment of osteoporosis accompanying the above morbid condition or occurring after ovariectony or menopause.

    摘要翻译： PCT No.PCT / JP94 / 00798 Sec。 371日期：1995年11月13日 102（e）1995年11月13日PCT PCT 1994年5月18日PCT公布。 WO94 / 26768 PCT公开号 日期1994年11月24日具有由下式（1）表示的雄激素衍生物作为活性成分的成骨促进剂和/或骨质疏松症药物：其中，每条虚线表示相关的碳 - 碳键是单键或双键或其盐。 化合物（1）激活成骨细胞，促进成骨并增加骨量，使其用于治疗由于老化，固定化，给予糖皮质激素等而降低成骨的病态。 此外，它可以通过其成骨促进作用增加骨量，使其可用于治疗伴随上述病态的骨质疏松症或卵巢发育或更年期后发生的骨质疏松症。

    Drug-containing sustained release microparticle, process for producing the same and preparation containing the microparticle
    28.
    发明授权
    Drug-containing sustained release microparticle, process for producing the same and preparation containing the microparticle 失效
    含药缓释微粒，其制造方法和含有微粒的制剂

    公开(公告)号：US08313767B2

    公开(公告)日：2012-11-20

    申请号：US12837810

    申请日：2010-09-02

    申请人： Yutaka Mizushima ,  Yasuaki Ogawa ,  Junzo Tanaka ,  Toshiyuki Ikoma

    发明人： Yutaka Mizushima ,  Yasuaki Ogawa ,  Junzo Tanaka ,  Toshiyuki Ikoma

    IPC分类号： A61K9/22 ,  A61K9/14 ,  A61K33/30 ,  A61K38/00 ,  A61K31/70 ,  A61K31/7088 ,  A61K31/56 ,  A61K31/315

    CPC分类号： A61K31/00 ,  A61K9/1611 ,  A61K33/30 ,  A61K33/42 ,  A61K45/06 ,  A61K2300/00

    摘要： Sustained release microparticles suitable for various types of drugs, or drug-containing sustained release microparticles capable of sustained release of drugs over a period of three days or more and capable of inhibiting initial burst release; a process for producing the same; and preparations containing the microparticles are disclosed. The drug-containing sustained release microparticles comprise a drug other than human growth hormone and a porous apatite derivative, and optionally include a water-soluble bivalent metal compound. The drug-containing sustained release microparticles can be produced by dispersing under agitation microparticles of a porous apatite derivative in an aqueous solution containing a drug so that the aqueous solution infiltrates into the porous apatite derivative; optionally adding an aqueous solution containing a water-soluble bivalent metal compound that may infiltrate into the porous apatite derivative; further adding additives such as a stabilizer to the mixture; and effecting lyophilization or vacuum drying.

    摘要翻译： 适用于各种类型药物的持续释放微粒，或能够在三天或更长时间内持续释放药物并且能够抑制初始爆发释放的药物持续释放微粒; 其制造方法; 并且公开了含有微粒的制剂。 含药物的缓释微粒包含除人生长激素以外的药物和多孔磷灰石衍生物，任选地包含水溶性二价金属化合物。 含药缓释微粒可以通过将多孔磷灰石衍生物的微粒分散在含有药物的水溶液中分散而制成，使得水溶液渗透到多孔磷灰石衍生物中; 任选地加入含有可渗透到多孔磷灰石衍生物中的水溶性二价金属化合物的水溶液; 进一步向混合物中加入稳定剂等添加剂; 并进行冻干或真空干燥。

    Lysolecithin derivatives
    29.
    发明授权
    Lysolecithin derivatives 失效
    溶血卵磷脂衍生物

    公开(公告)号：US5310958A

    公开(公告)日：1994-05-10

    申请号：US832585

    申请日：1992-02-07

    申请人： Yutaka Mizushima

    发明人： Yutaka Mizushima

    IPC分类号： A61K38/28 ,  A61K38/43 ,  A61K38/44 ,  A61K39/44 ,  C07F9/10 ,  C07C233/00

    CPC分类号： A61K47/48053 ,  A61K38/446 ,  A61K39/44 ,  C07F9/10 ,  C12Y115/01001

    摘要： A modified biologically active protein consisting essentially of a biologically active protein bonded to lecithin via a covalent linking group and a pharmaceutical composition comprising the modified biologically active protein in a pharmaceutically acceptable carrier. The biologically active proteins include antibodies, superoxide dismutase, insulin and callidinogenase. Lecithin derivatives are also disclosed.

    摘要翻译： 基本上由经由共价连接基团与卵磷脂结合的生物活性蛋白质和在药学上可接受的载体中包含修饰的生物活性蛋白质的药物组合物组合的修饰的生物活性蛋白质。 生物活性蛋白包括抗体，超氧化物歧化酶，胰岛素和愈伤组蛋白酶。 还公开了卵磷脂衍生物。

    Fat emulsions containing isocarbacyclin
    30.
    发明授权
    Fat emulsions containing isocarbacyclin 失效
    含有异卡巴环素的脂肪乳剂

    公开(公告)号：US5124352A

    公开(公告)日：1992-06-23

    申请号：US727376

    申请日：1991-07-05

    申请人： Yutaka Mizushima ,  Yoko Shoji ,  Yasuko Yagyu ,  Seizi Kurozumi

    发明人： Yutaka Mizushima ,  Yoko Shoji ,  Yasuko Yagyu ,  Seizi Kurozumi

    IPC分类号： A61K9/10 ,  A61K9/107 ,  A61K31/34 ,  A61K31/557

    CPC分类号： A61K31/34 ,  A61K31/557 ,  A61K9/1075

    摘要： The fat emulsions containing the prostaglandin I.sub.2 's expressed by the following formula (I): ##STR1## where X represents an oxygen atom to a methine group, Y is a carbon atom, Z represents a methylene or methine group; when X is an oxygen atom, the mode of Y-Z binding is a double bond of carbon-carbon, and when X is a methine group, the mode of X-Y binding is a double bond of carbon-carbon and Z is a methylene group; R.sub.1 represents a hydrogen atom or alkyl group, R.sub.2 represents a hydrogen atom or fluorine atom, and R.sub.3 represents a hydrogen atom, methyl group, ethyl group or vinyl group. R.sub.4 represents a substituted or unsubstituted alkyl group with 1-10 carbon atoms, a substituted or unsubstituted alkenyl group with 2-10 carbons atoms, a substituted or unsubstituted alkynyl group with 2-10 carbon atoms, or a substituted or unsubstituted cycloalkyl group with 3-8 carbon atoms; and n is zero (0) or an integer of value 1.

    摘要翻译： 含有由下式（I）表示的前列腺素I2的脂肪乳剂：其中X表示次甲基的氧原子，Y为碳原子，Z表示亚甲基或次甲基; 当X是氧原子时，Y-Z结合的方式是碳 - 碳的双键，当X是次甲基时，X-Y结合的方式是碳 - 碳的双键，Z是亚甲基。 R1表示氢原子或烷基，R2表示氢原子或氟原子，R3表示氢原子，甲基，乙基或乙烯基。 R 4表示具有1-10个碳原子的取代或未取代的烷基，具有2-10个碳原子的取代或未取代的烯基，具有2-10个碳原子的取代或未取代的炔基或具有3个 -8个碳原子; 并且n为零（0）或值为1的整数。